(Q39744502)

14 September 2017

title

Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity (English)

1 reference

14 September 2017

1 reference

5

1 reference

14 September 2017

Mimi Liu

1

1 reference

14 September 2017

Zhi Jun Lim

series ordinal

2

1 reference

14 September 2017

Yee Yen Gwee

series ordinal

3

1 reference

14 September 2017

Aviva Levina

series ordinal

4

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Angewandte Chemie International Edition

14 September 2017

published in

0 references

volume

49

1 reference

14 September 2017

issue

9

1 reference

14 September 2017

page(s)

1661-1664

1 reference

Recent developments in ruthenium anticancer drugs

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

A potential role for protein tyrosine phosphatase inhibition by a RuIII-edta complex (edta = ethylenediaminetetraacetate) in its biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Ruthenium complexes can target determinants of tumour malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

X-ray absorption and EPR spectroscopic studies of the biotransformations of chromium(VI) in mammalian cells. Is chromodulin an artifact of isolation methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Reactivity of chromium(III) nutritional supplements in biological media: an X-ray absorption spectroscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Reactivity of potential anti-diabetic molybdenum(VI) complexes in biological media: a XANES spectroscopic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Hypoxia increases human keratinocyte motility on connective tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

A novel assay for the quantification of invasion from raft cultures of lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Ruthenium Anticancer Compounds: Challenges and Expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

Biomedical applications of X-ray absorption and vibrational spectroscopic microscopies in obtaining structural information from complex systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906079

21 January 2018

Identifiers

DOI

10.1002/ANIE.200906079

1 reference

14 September 2017

1 reference